Decreased active TGF-β2 levels in the aqueous humour during immune reactions following penetrating keratoplasty

Eye

Volumn 22, Issue 4, 2008, Pages 569-575

  Maier, P ^a   Broszinski, A ^a   Heizmann, U ^a   Reinhard, T ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; CORTICOSTEROID; CYCLOSPORIN A; EYE DROPS; GENTAMICIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE ACETATE; TRANSFORMING GROWTH FACTOR BETA2;

ACANTHAMOEBA KERATITIS; ANTERIOR EYE CHAMBER; AQUEOUS HUMOR; ARTICLE; CATARACT; CATARACT EXTRACTION; CLINICAL ARTICLE; CONTROLLED STUDY; CORNEA TRANSPLANTATION; DRUG DOSE REDUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; GENERAL ANESTHESIA; GLAUCOMA; GRAFT FAILURE; GRAFT INFECTION; HERPES SIMPLEX KERATITIS; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; NON INSULIN DEPENDENT DIABETES MELLITUS; PENETRATING KERATOPLASTY; POSTOPERATIVE PERIOD; PREDICTION; REOPERATION; STATISTICAL SIGNIFICANCE; TOPICAL ANESTHESIA;

EID: 42449122222     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/sj.eye.6703028     Document Type: Article

References (44)

1. Callanan D, Peeler J, Niederkorn JY. Characteristics of rejection of orthotopic corneal allografts in the rat. Transplantation 1988; 45(2): 437-443.
2. Niederkorn JY. The induction of anterior chamber-associated immune deviation. Chem Immunol Allergy 2007; 92: 27-35.
3. Streilein JW. Unraveling immune privilege. Science 1995; 270 5239): 1158-1159.
4. Yamada J, Streilein JW. Induction of anterior chamber-associated immune deviation by corneal allografts placed in the anterior chamber. Invest Ophthalmol Vis Sci 1997; 38(13): 2833-2843.
5. Williams, KA, Muehlberg SM, Lewis RF, Coster DJ. How successful is corneal transplantation? A report from the Australian Corneal Graft Register. Eye 1995; 9(Part 2): 219-227.
6. Claesson M, Armitage WJ, Fagerholm F, Stenevi U. Visual outcome in corneal grafts: An preliminary analysis of the Swedish Corneal Transplant Register. Br J Ophthalmol 2002; 86(2): 174-180.
7. Kawashima H, Prasad SA, Gregerson DS. Corneal endothelial cells inhibit T cell proliferation by blocking IL-2 production. J Immunol 1994; 153(5): 1982-1989.
8. Knisely TL, Bleicher PA, Vibbard CA, Granstein RD. Production of latent transforming growth factor-beta and other inhibitory factors by cultured murine iris and ciliary body cells. Curr Eye Res 1991; 10 8): 761-771.
9. Peress NS, Perillo E. TGF-beta 2 and TGF-beta 3 immunoreactivity within the ciliary epithelium [corrected]. Invest Ophthalmol Vis Sci 1994; 35(2): 453-457.
10. Tripathi RC, Chan WF, Li J, Tripathi BJ. Trabecular cells express the TGF-beta 2 gene and secrete the cytokine. Exp Eye Res 1994; 58 5): 523-528.
11. Sano Y, Okamoto S, Streilein J-W. Induction of donor-specific ACAID can prolong orthotopic corneal allograft survival in 'high-risk' eyes. Curr Eye Res 1997; 16(11): 1171-1174.
12. Wilson SE, Lloyd SA. Epidermal growth factor and its receptor, basic fibroblast growth factor, transforming growth factor beta-1, and interleukin-1 alpha messenger RNA production in human corneal endothelial cells. Invest Ophthalmol Vis Sci 1991; 32(10): 2747-2756.
13. Link H XB. Transforming Growth Factor β, Vol. 2nd ed. Academic Press, San Diego, 1998 pp 2392-2399.
14. Cousins SW, McCabe MM, Danielpour D, Streilein JW. Identification of transforming growth factor-beta as an immunosuppressive factor in aqueous humor. Invest Ophthalmol Vis Sci 1991; 32(8): 2201-2211.
15. Reinhard T. Bonig H, Mayweg S, Bohringer D, Gobel U, Sundmacher R. Soluble Fas ligand and transforming growth factor beta2 in the aqueous humor of patients with endothelial immune reactions after penetrating keratoplasty. Arch Ophthalmol 2002; 120(12): 1630-1635.
16. Khalil N. TGF-beta: From latent to active. Microbes Infect 1999; 1(15): 1255-1263.
17. Zamiri P, Masli S, Kitaichi N, Taylor AW, Streilein JW. Thrombospondin plays a vital role in the immune privilege of the eye. Invest Ophthalmol Vis Sci 20055; 46(3): 908-919.
18. Neurohr C, Nishimura SL, Sheppard D. Activation of transforming growth factor-beta by the integrin alphavbeta8 delays epithelial wound closure. Am J Respir Cell Mol Biol 2006; 35(2): 252-259.
19. Maier P, Broszinski A, Heizmann U, Boehringer D, Reinhard T. Determination of active TGF-beta 2 in aqueous humor prior to and following cryopreservation. Mol Vis 2006; 12: 1477-1482.
20. Maier P, Broszinski A, Heizmann U, Boehringer D, Reinhard T. Active transforming growth factor-beta2 is increased in the aqueous humor of keratoconus patients. Mol Vis 2007; 13: 1198-1202.
21. Reinhard T Sundmacher R. Adjunctive intracameral application of corticosteroids in patients with endothelial immune reactions after penetrating keratoplasty: A pilot study. Transpl Int 2002; 15 2-3): 81-88.
22. Hoffmann F. [Suture technique for perforating keratoplasty (author's transl)]. Klin Monatsbl Augenheilkd 1976; 169(5): 584-590.
23. Reinhard T, Bohringer D, Huschen D, Sundmacher R. [Chronic endothelial cell loss of the graft after penetrating keratoplasty: Influence of endothelial cell migration from graft to host]. Klin Monatsbl Augenheilkd 2002; 219(6): 410-416.
24. Mayer K, Reinhard T, Reis A, Voiculescu A, Sundmacher R. Synergistic antiherpetic effect of acyclovir and mycophenolate mofetil following keratoplasty in patients with herpetic eye disease: First results of a randomised pilot study. Graefes Arch Clin Exp Ophthalmol 2003; 241(12): 1051-1054.
25. Reis A, Reinhard T, Voiculescu A, Kutkuhn B, Godehardt E, Spelsberg H et al. Mycophenolate mofetil versus cyclosporin A in high risk keratoplasty patients: A prospectively randomised clinical trial. Br J Ophthalmol 1999; 83(11): 1268-1271.
26. Reinhard Y, Sundmacher R, Godehardt E, Heering P. [Preventive systemic cyclosporin A after keratoplasty at increased risk for immune reaction as the only elevated risk factor]. Ophthalmologe 1997; 94 7): 496-500.
27. Alvarez de Toledo J, Armitage WJ, Ponzin D, Tullo A. EEBA standards 2007. http://www.europeaneyebanks.org/public/_cfm/page/page471.cfm.
28. Min SH, Lee, TI, Chung YS, Kim HK. Transforming growth factor-beta levels in human aqueous humor of glaucomatous, diabetic and uveitic eyes. Korean J Opthalmol 2006; 20(3): 162-165.
29. Yamamoto N, Itonaga K, Marunouchi T, Majima K. Concentration of transforming growth factor beta2 in aqueous humor. Ophthalmic Res 2005; 37(1): 29-33.
30. Knisely TL, Hosoi J, Nazareno R, Granstein RD. The presence of biologically significant concentrations of glucocorticoids but little or no cortisol binding globulin within aqueous humor: Relevance to immune privilege in the anterior chamber of the eye. Invest Ophthalmol Vis Sci 1994; 35(10): 3711-3723.
31. Wallentin N, Lundberg C. Steroid and anti-CD18 treatment have no effect on after-cataract formation following surgery in rabbits. Curr Eye Res 2000; 20(5): 384-393.
32. Wakefield L, Kim SJ, Glick A, Winokur T, Colletta A, Sporn M. Regulation of transforming growth factor-beta subtypes by members of the steroid hormone superfamily. J Cell Sci Suppl 1990; 13: 139-148.
33. Tripathi RC, Li J, Chan WF, Tripathi BJ. Aqueous humor in glaucomatous eyes contains an increased level of TGF-beta 2. Exp Eye Res 1994; 59(6): 723-727.
34. Inatani M, Tanihara H, Katsuta H, Honjo M, Kido N, Honda Y. Transforming growth factor-beta 2 levels in aqueous humor of glaucomatous eyes. Graefes Arch Clin Exp Ophthalmol 2001; 239(2): 109-113.
35. Picht G, Welge-Luessen U, Grehn F, Lutjen-Drecoll E. Transforming growth factor beta 2 level in the aqueous humor in different types of glaucoma and the relation to filtering bleb development. Graefes Arch Clin Exp Ophthalmol 2001; 239(3): 199-207.
36. Wimmer I, Welge-Luessen U, Picht G, Grehn F. Influence of argon laser trabeculoplasty on transforming growth factor-beta 2 concentration and bleb scarring following trabeculectomy. Graefes Arch Clin Exp Ophthalmol 2003; 241(8): 631-636.
37. Ochiai Y, Ochiai H. Higher concentration of transforming growth factor-beta in aqueous humor of glaucomatous eyes and diabetic eyes. Jpn J Ophthalmol 2002; 46(3): 249-253.
38. Bohringer D, Reinhard T, Spelsberg H, Sundmacher R. influencing factors on chronic endothelial cell loss characterised in a homogeneous group of patients. Br J Ophthalmol 2002; 86(1): 35-38.
39. Ardjomand N, Berghold A, Reich ME. Loss of corneal Langerhans cells during storage in organ culture medium, Optisol and McCarey-Kaufman medium. Eye 1998; 12 (Part 1): 134-138.
40. Kuchle M, Cursiefen C, Nguyen NX, Langenbucher A, Seitz B, Wenkel H et al. Risk factors for corneal allograft rejection: Intermediate results of a prospective normal-risk keratoplasty study. Graefes Arch Clin Exp Ophthalmol 2002; 240(7): 580-584.
41. Smiddy WE, Stark WJ, Young E, Klein PE, Bians, WD, Maumenee AE. Clinical and immunological results of corneal allograft rejection. Ophthalmic Surg 1986; 17(10): 644-649.
42. Schultz-Cherry S, Murphy-Ullrich JE. Thrombospondin causes activation of latent transforming growth factor-beta secreted by endothelial cells by a novel mechanism. J Cell Biol 1993; 122(4): 923-932.
43. Taylor AW, Yee DC. Somatostatin is an immunosuppressive factor in aqueous humor. Invest Ophthalmol Vis Sci 2003; 44(6): 2644-2649.
44. Taylor AW, Streilein JW, Cousins SW. Identification of alpha-melanocyte stimulating hormone as a potential immunosuppressive factor in aqueous humor. Curr Eye Res 1992; 11(12): 1199-1206.